Company Overview and News
Three 2x Leveraged High-Yield Monthly Pay Mortgage REIT ETNs all have very high yields, but at times may trade at prices which may present risk-free arbitrage opportunities.
SLDA DTK RC ABRN REM CMO TWO 8685 GPMT AJXA HASI ABR CEFL AVF DX AIG ABRN.CL AJX
2018-10-01 seekingalpha - 1
There is much uncertainty as to the future path of the equity and bond markets. This suggests diversification may be more important than usual.
STAR DTK ORC ABRN REM UBS CMO TWO AGNC HASI ABR AAL DX ARR ABRN.CL ULSGF
2018-09-24 seekingalpha - 1
This article compares NLY’s recent dividend per share rates, yield percentages, and several dividend sustainability metrics to 19 mREIT peers.
ANH NYMTO ORC CHMI NYMTP AI CIM CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT
cmo-8k_20180822.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
2018-08-15 seekingalpha - 2
Part 1 of this article compares NLY’s recent leverage, hedging coverage ratio, quarterly BV, economic loss, and current valuation to twenty mREIT peers.
ANH NYMTO ORC CHMI NYMTP CIM AI CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT
2018-08-01 seekingalpha - 1
On 7/25/2018, AGNC reported results for the second quarter of 2018. AGNC reported comprehensive income of $148 million and a non-tangible BV as of 6/30/2018 of $19.68 per common share.
NYMTO ORC CHMI NYMTP AI CMO TWO AGNC AIW MO NRZ AIC CYS ARR BXMT 511505 NYMT CAPITALT
cmo-10q_20180630.htm UNITED STATES
Capstead Mortgage Corporation (NYSE:CMO) Q2 2018 Results Earnings Conference Call July 26, 2018 9:00 AM ET
cmo-8k_20180725.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
2018-07-03 seekingalpha - 1
The performance of 59 securities, which were selected by SA contributors for their high-yield portfolios in 2014, are identified and analyzed for the period May 2014 to July 2018.
AIY AINV ARI PCI NYMTO HTF KAP OSLE NYMTP KCAP FGB AI CMO TWO SDRL HTFA AGNC AIW SLRA RSO WMC AIC AIB TCRD PSEC NMFC CYS AIF TSLF MCX SCQ XAN PBB SCA MCQ HRZN CHW OXLCO MCV OXLCN STWD.WI MITT SCM HTGZ SLRC BIT MCC TCRX ARCC GBDC CLMT MFO DX NLY TCPC TCRZ HTGX OXLC HTGY ARU OCSL EFC MFA NYMT HTGC STWD
The July 2018 REML dividend will bring, on a monthly compounded annualized rate, its yield to 22.2%.
SLDA STAR ANH ORC MITT BAC REM LADR TRTX CMO KREF AGNC RWT GPMT ABR GE GEC CEFL HOG ARR XAN SLD GNE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to CMO / Capstead Mortgage Corp. on message board site Silicon Investor.
as of ET